Mansour AA, Gonçalves JT, Bloyd CW, Li H, Fernandes S, Quang D, et al. An in vivo model of functional and vascularized human brain organoids. Nat Biotechnol. 2018;36(5):432–41.
National Acadamy of Sciences. Guidelines for human embryonic stem cell research. Washington, D.C.; 2005.
National Acadamy of Sciences. The emerging field of human neural organoids, transplants, and chimeras. The emerging field of human neural Organoids, transplants, and chimeras; 2021.
Directorate-General for Health and Food Safety, European Commission. Proposal for a Regulation of the European Parliament and of the Council on standards of quality and safety for substances of human origin intended for human application and repealing Directives 2002/98/EC and 2004/23/EC. Brussels; 2022.
European Parliament and the Council of the European Union. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004, Vol. L. Brussels: Official Journal of the European Union; 2007.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.
Oksdath M, Perrin SL, Bardy C, Hilder EF, DeForest CA, Arrua RD, et al. Review: synthetic scaffolds to control the biochemical, mechanical, and geometrical environment of stem cell-derived brain organoids. APL Bioeng. 2018;2(4):41501.
Garreta E, Kamm RD, de Sousa C, Lopes SM, Lancaster MA, Weiss R, et al. Rethinking organoid technology through bioengineering. Nat Mater. 2021;20(2):145–55.
Lancaster MA, Huch M. Disease modelling in human organoids. DMM. Dis Model Mech. 2019;12(7):dmm039347.
Andrews MG, Nowakowski TJ. Human brain development through the lens of cerebral organoid models. Brain Res. 2019;1725:146470.
Walker MJ, Nielsen J, Goddard E, Harris A, Hutchison K. Induced pluripotent stem cell-based Systems for Personalising Epilepsy Treatment: research ethics challenges and new insights for the ethics of personalised medicine. AJOB Neurosci. 2022;13(2):120–31.
Harris AR, Walker MJ, Gilbert F, McGivern P. Investigating the feasibility and ethical implications of phenotypic screening using stem cell-derived tissue models to detect and manage disease. Stem Cell Reports. 2022;17(5):1023–32.
Kiatpongsan S, Sipp D. Monitoring and regulating offshore stem cell clinics. Science (80- ). 2009;323(5921):1564–5.
Lv J, Su Y, Song L, Gong X, Peng Y. Stem cell ‘therapy’ advertisements in China: Infodemic, regulations and recommendations. Cell Prolif. 2020;53(12):e12937.
U.S. Food and Drug Administration (FDA). Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use. Silver Spring: Guidance for Industry and Food and Drug Administration Staff; 2020. FDA-2017-D-6146-0001.
Chirba M, Noble A. Our bodies, our cells: FDA regulation of autologous adult stem cell therapies: Bill of Health (Boston College Law School Faculty Papers); 2013.
Lysaght T, Campbell AV. Broadening the scope of debates around stem cell research. Bioethics. 2013;27(5):251–6.
Berkowitz AL, Miller MB, Mir SA, Cagney D, Chavakula V, Guleria I, et al. Glioproliferative lesion of the spinal cord as a complication of “stem-cell tourism”. N Engl J Med. 2016;375(2):196–8.
Thirabanjasak D, Tantiwongse K, Thorner PS. Angiomyeloproliferative lesions following autologous stem cell therapy. J Am Soc Nephrol. 2010;21(7):1218 LP–1222.
Ballantyne C. Fetal stem cells cause tumor in a teenage boy. Sci Am. 2009. Available from: https://blogs.scientificamerican.com/news-blog/embryonic-stem-cells-cause-cancer-i-2009-02-19/#:~:text=The%20tumor%20was%20benign%2C%20doctors,of%20Scientific%20American%20and%20elsewhere.
Jabr F. In the flesh: the embedded dangers of untested stem cell cosmetics. Sci Am. 2012. Available from: https://www.scientificamerican.com/article/stem-cell-cosmetics/.
Kuriyan AE, Albini TA, Townsend JH, Rodriguez M, Pandya HK, Leonard RE, et al. Vision loss after Intravitreal injection of autologous “stem cells” for AMD. N Engl J Med. 2017;376(11):1047–53.
Mehat MS, Sundaram V, Ripamonti C, Robson AG, Smith AJ, Borooah S, et al. Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration. Ophthalmology. 2018;125(11):1765–75.
Mandai M, Watanabe A, Kurimoto Y, Hirami Y, Morinaga C, Daimon T, et al. Autologous induced stem-cell–derived retinal cells for macular degeneration. N Engl J Med. 2017;376(11):1038–46.
Hess DC, Wechsler LR, Clark WM, Savitz SI, Ford GA, Chiu D, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(5):360–8.
Reardon S. First pig-to-human heart transplant: what can scientists learn? Nature. 2022;601:305–6.
Gilbert F, Harris AR, Kapsa RMI. Efficacy testing as a primary purpose of phase 1 clinical trials: is it applicable to first-in-human bionics and Optogenetics trials? AJOB Neurosci. 2012;3(2):20–2.
Gilbert F, Harris AR, Kapsa RMI. Controlling brain cells with light: ethical considerations for Optogenetic clinical trials. AJOB Neurosci. 2014;5(3):3–11.
Xu L, Wang J, Liu Y, Xie L, Su B, Mou D, et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. N Engl J Med. 2019;381(13):1240–7.
Lysaght T, Lipworth W, Hendl T, Kerridge I, Lee T-L, Munsie M, et al. The deadly business of an unregulated global stem cell industry. J Med Ethics. 2017;43(11):744 LP–746.
Turner L. The US direct-to-consumer marketplace for autologous stem cell interventions. Perspect Biol Med. 2018;61(1):7–24.
Sipp D. Challenges in the regulation of autologous stem cell interventions in the United States. Perspect Biol Med. 2018;61(1):25–41.
www.isscr.org/policy/guidelines-for-stem-cell-research-and-clinical-translation. ISSCR guidelines for stem cell science and clinical translation. 2021.
Uhlhaas PJ, Singer W. Neural synchrony in brain disorders: relevance for cognitive dysfunctions and pathophysiology. Neuron. 2006;52(1):155–68.
Paşca AM, Sloan SA, Clarke LE, Tian Y, Makinson CD, Huber N, et al. Functional cortical neurons and astrocytes from human pluripotent stem cells in 3D culture. Nat Methods. 2015;12(7):671–8.
Tomaskovic-Crook E, Zhang P, Ahtiainen A, Kaisvuo H, Lee CY, Beirne S, et al. Human neural tissues from neural stem cells using conductive biogel and printed polymer microelectrode arrays for 3D electrical stimulation. Adv Healthc Mater. 2019;8(15):1900425.
U.S. Food and Drug Administration (FDA). Preclinical assessment of investigational cellular and gene therapy products. Silver Spring; 2013. FDA-2012-D-1038.
U.S. Food and Drug Administration (FDA). Considerations for the design of early-phase clinical trials of cellular and gene therapy products. Silver Spring; 2015. FDA-2013-D-0576.
Hyun I, Taylor P, Testa G, Dickens B, Jung KW, McNab A, et al. Ethical standards for human-to-animal chimera experiments in stem cell research. Cell Stem Cell. 2007;1(2):159–63.
Harris A. Comment to human-specific gene ARHGAP11B promotes basal progenitor amplification and neocortex expansion. Science. 2015;347:1465–70.
Chen HI, Wolf JA, Blue R, Song MM, Moreno JD, Ming G, et al. Transplantation of human brain Organoids: revisiting the science and ethics of brain chimeras. Cell Stem Cell. 2019;25(4):462–72.
Harris AR, McGivern P, Ooi L. Modeling emergent properties in the brain using tissue models to investigate neurodegenerative disease. Neuroscientist. 2020;26(3):224–30.
Koplin JJ, Savulescu J. Moral limits of brain Organoid research. J Law, Med Ethics. 2019;47(4):760–7.
Ohayon EL, Tsang PW, Lam A. A computational window into the problem with organoids: approaching minimal substrates for consciousness. Washington, D.C.: Society for Neuroscience; 2019.
Kagan BJ, Duc D, Stevens I, Gilbert F. Neurons embodied in a virtual world: evidence for Organoid ethics? AJOB Neurosci. 2022;13(2):114–7.
Shepherd J. Consciousness and moral status. Consciousness and moral status: Taylor & Francis; 2018.
Jaworska A, Tannenbaum J. The Grounds of Moral Status [Internet]. Available from: http://plato.stanford.edu/entries/grounds-moral-status/
Lavazza A, Massimini M. Cerebral organoids: ethical issues and consciousness assessment. J Med Ethics. 2018;44(9):606 LP–610.
Lavazza A. Potential ethical problems with human cerebral organoids: consciousness and moral status of future brains in a dish. Brain Res. 2021;1750:147146.
Hansson SO. Implant ethics. J Med Ethics. 2005;31(9):519 LP–525.
Gilbert F. Self-Estrangement & Deep Brain Stimulation: ethical issues related to forced Explantation. Neuroethics. 2015;8(2):107–14.
Gilbert F, Viaña JNM, Ineichen C. Deflating the “DBS causes personality changes” bubble. Neuroethics. 2021;14(1):1–17.
Gilbert F, Viaña JN. A personal narrative on living and dealing with psychiatric symptoms after DBS surgery. Narrat Inq Bioeth. 2018;8(1):67–77.
Klaming L, Haselager P. Did my brain implant make me do it? Questions raised by DBS regarding psychological continuity, responsibility for action and mental competence. Neuroethics. 2013;6(3):527–39.
Chadwick RF. The market for bodily parts: Kant and duties to oneself. J Appl Philos. 1989;6(2):129–40.
Svenaeus F. The body as gift, resource or commodity? Heidegger and the ethics of organ transplantation. J Bioeth Inq. 2010;7(2):163–72.
Gold E. Body parts: property rights and the ownership of human biological materials. Washington, D.C.: Georgetown University Press; 1997.
Fiduciary Duty of Researchers - the Spleen Case - Moore v. Regents of University of California, 793 P.2d 479 (Cal. 1990) [Internet]. 1998. Available from: https://biotech.law.lsu.edu/cases/consent/Moore_v_Regents.htm
Allen MJ, Powers MLE, Gronowski KS, Gronowski AM. Human tissue ownership and use in research: what Laboratorians and researchers should know. Clin Chem. 2010;56(11):1675–82.
Wall J. Being and owning: the body, bodily material, and the law. Oxford: Oxford University Press; 2015. p. 235.
Dickenson D. Property in the body: feminist perspectives. In: Cambridge bioethics and law. 2nd ed. Cambridge: Cambridge University Press; 2017.
Www.isscr.org/docs/default-source/policy-documents/isscr-informed-consent-standards-for-stem-cell-based-interventions.pdf. Informed Consent Standard for Stem Cell-Based Interventions Offered Outside of Formal Clinical Trials. 2019;
Greely HT. Human brain surrogates research: the onrushing ethical dilemma. Am J Bioeth. 2021;21(1):34–45.
Marks PW, Witten CM, Califf RM. Clarifying stem-cell Therapy’s benefits and risks. N Engl J Med. 2016;376(11):1007–9.
Gilbert F, Viaña JNM, O’Connell CD, Dodds S. Enthusiastic portrayal of 3D bioprinting in the media: ethical side effects. Bioethics. 2018;32(2):94–102.
Gilbert F, O’Connell CD, Mladenovska T, Dodds S. Print me an organ? Ethical and regulatory issues emerging from 3D bioprinting in medicine. Sci Eng Ethics. 2018;24(1):73–91.
Harris AR, Gilbert F. Military medicine research: incorporation of high risk of irreversible harms into a stratified risk framework for clinical trials. In: Health Care in Contexts of risk, uncertainty, and hybridity military and humanitarian health ethics: Springer; 2022. p. 253–73.
Baer AR, Devine S, Beardmore CD, Catalano R. Clinical investigator responsibilities. J Oncol Pract. 2011;7(2):124–8.
Feehan AK, Garcia-Diaz J. Investigator responsibilities in clinical research. Ochsner J. 2020;20(1):44–9.
Dubinsky PM, Henry KA. The fundamentals of clinical research: a universal guide for implementing good clinical practice: Wiley; 2022. p. 2–5.